3 ms·
As far as I'm aware the majority of failing biotech companies have very broadly targeted Amyloid beta (apparently because they thought it was a good risk tradeo
by alakin 8y ago
As far as I'm aware the majority of failing biotech companies have very broadly targeted Amyloid beta (apparently because they thought it was a good risk tradeoff). A narrow focus on APOE4 could be a wiser strategy. I could even see gene therapy playing a role.
- aaavl2821 8y agoThere are a few well funded startups targeting apoe4 and other genetic markers of neurodegen disease. Exciting field